BEAM trial: Bevacizumab survival gains are short of significant: Commentary

Research output: Contribution to journal › Comment/debate › peer-review

ASJC Scopus subject areas

This output contributes to the following UN Sustainable Development Goals (SDGs)

TY - JOUR

T1 - BEAM trial

T2 - Bevacizumab survival gains are short of significant: Commentary

AU - Sosman, Jeffrey A.

PY - 2009/12/1

Y1 - 2009/12/1

UR - https://www.scopus.com/pages/publications/78650274115

UR - https://www.scopus.com/inward/citedby.url?scp=78650274115&partnerID=8YFLogxK

M3 - Comment/debate

AN - SCOPUS:78650274115

SN - 1548-5323

JO - Oncology Report

JF - Oncology Report

IS - WINT

ER -